Search

Objective To evaluate the therapeutic effect of Yiqi Yangyin prescription for dilated cardiomyopathy (DCM). Methods Electronic databases were searched for relevant clinical randomized controlled trials of DCM treatment using Yiqi Yangyin prescription (Shengmai and Zhigancao decoction). Databases searched included PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure Database, Wanfang Database, China Science and Technology Journal Database, and Chinese Biological Medicine from January 1, 1985, to October 31, 2015. After literature screening and data extraction according to previously determined exclusion criteria, data were analyzed using RevMan 5.3 and Stata 12.0. Study heterogeneity was evaluated using the I 2 test and Cochran's Q test. Egger's test was used to detect publication bias. Results Nineteen trials involving 1024 participants were included in the Meta-analysis. Of these, 15 used Shengmai (treatment group: 421 cases; control group: 344 cases) and 4 used Zhigancao decoction (treatment group: 133 cases; control group: 126 cases). A Meta-analysis demonstrated that the total curative effect was significantly improved by combining Shengmai with conventional treatment [relative risk ( RR ) = 1.32, 95% confidence intervals ( CI ) (1.22, 1.43), P SMD ) = 1.13, 95% CI (0.55, 1.70), P SMD = −0.46, 95% CI (−0.70, −0.23), P RR = 1.34, 95% CI (1.16, 1.54), P Conclusion Compared with conventional therapy, Yiqi Yangyin prescription can significantly improve the curative effect, increase left ventricular ejection fraction, and reduce left ventricular end diastolic. Thus, it can effectively improve heart function in patients with DCM.

ObjectiveTo observe the effect of Liandouqingmai recipe (Chinese herbal medicine compound preparation) on the quality of life (QOL) and inflammatory reaction of patients with coronary heart disease (CHD).MethodsA total of 101 CHD patients were randomized into two groups: treatment group (n=45) receiving standard treatment for CHD plus Liandouqingmai recipe, and control group (n=56) receiving standard treatment only. The control group contained 16 normal healthy subjects. Changes in hs-C-reactive protein (CRP), peripheral blood leucocytes (PBL), and interleukin (IL)-6 and IL-10 levels were measured. The Seattle Angina Questionnaire (SAQ) was used to determine patient QOL before and after treatment for 2 weeks.ResultsBefore treatment, SAQ scores [physical limitation (PL), angina stability (AS), angina frequency (AF), treatment satisfaction (TS), and disease perception (DP)] were not statistically different between groups. After treatment, AS and DP levels of controls were significantly increased compared with the other groups, while PL, AS, AF, TS, and DP levels of the treatment group were significantly increased compared with controls. Treatment group SAQ scores (PL, AS, AF, TS, and DP) were significantly higher than for controls. CHD patient IL-6 and IL-10 levels were significantly higher than controls. Before treatment, mean levels of IL-6, hs-CRP and PBL of the two groups were not statistically different. After treatment, mean levels of IL-6, IL-10, hs-CRP and PBL of the two groups were significantly decreased compared with their before treatment values, and levels of IL-6, hs-CRP, and PBL of the treatment group were lower than controls. Although mean IL-10 levels of both groups decreased, there was no significant difference in between-group and in-group comparisons before and after treatment. Mean levels of IL-6 and IL-10 in the normal group were lower than in CHD patients. SAQ scores of QOL were negatively associated with the inflammatory index (IL-6/IL-10), and there was a significant negative association of IL-10 with AS (r= − 0.15, P